Artrya Limited (ASX: AYA) has secured AU$15 million in binding commitments through a two-tranche placement at AU$0.73 per share, supporting the commercial expansion of its AI-driven coronary disease detection platform. The funds will accelerate regulatory applications for Salix Coronary Plaque and Salix Coronary Flow, drive customer implementation, support clinical studies, and fund research & development, regulatory costs, and working capital.
A significant portion of the funds will also initiate the SAPPHIRE study, a flagship plaque study designed to establish broad clinical credibility and enhance the commercial adoption of Salix software in US hospital centres. The company expects FDA clearance for its Salix Coronary Anatomy product by March 2025. Artrya CEO Mathew Regan emphasized the strategic importance of this funding in advancing regulatory approvals, expanding market presence, and solidifying Artrya’s footprint in the global healthcare industry.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 20, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
